AstraZeneca's ‘radiosensitizer’ may enhance efficacy of radiation for deadly brain cancer
09 Apr 2024
Radiation Therapy
Researchers are testing an experimental drug developed by AstraZeneca with radiation to see if pairing the treatments will boost radiation’s efficacy in glioblastoma, a notoriously difficult cancer to treat.
The AstraZeneca treatment, dubbed AZD1390, inhibits a DNA repair enzyme called ATM. AZD1390 is meant to act as a “radiosensitizer”; it aims to prevent DNA from repairing after radiation damages the DNA in cancer cells. And preclinical data have suggested that tumor tissue appears especially vulnerable to AZD1390’s repair inhibition, radiation oncologist Jonathan Yang told Endpoints News.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.